Intestinal differentiated mucinous adenocarcinoma of the endometrium with sporadic MSI high status: a case report

Diagnostic Pathology
Mafalda TrippelTilman T Rau

Abstract

Intestinal differentiation of primary mucinous adenocarcinoma of the uterine corpus is exceedingly rare in comparison to the approximately 25% rate in endocervical and ovarian mucinous carcinoma. Additionally, little is known about the related genetic and epigenetic alterations, even though large-scale molecular characterisation of the different types of endometrial cancer took place in the TCGA project along the entities defined by the recent WHO classification. We present a 62-year-old patient harbouring a primary mucinous carcinoma of the uterine corpus with a morphological resemblance to mucinous colorectal adenocarcinoma. The intestinal differentiation was substantiated by CDX2 and CK20 positivity in the absence of PAX8, p16, WT1, p53, ER, PgR, AFP, SALL4 and Glypican3. A high MSI status with MLH1 hypermethylation was revealed by molecular testing. Intestinal differentiation of mucinous adenocarcinoma of the endometrium is a unique observation. Besides morphology, it obviously can share molecular features of sporadic MSI colorectal cancers. It can be speculated that either CDX2 positive morula formation or intestinal metaplasia of the endometrium as rare conditions might be the origin of carcinogenesis for this type II end...Continue Reading

References

Jul 1, 1995·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·W G McCluggageH Bharucha
Jul 20, 2004·The Journal of Pathology·Gerhard FallerThomas Brabletz
Apr 12, 2006·The Journal of International Medical Research·K TomiyamaM Soda
Sep 9, 2008·Applied Immunohistochemistry & Molecular Morphology : AIMM·Kay J ParkEdyta C Pirog
Dec 4, 2010·Journal of Clinical Pathology·Alina NicolaeFrancisco F Nogales
Aug 2, 2011·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Alina NicolaeFrancisco F Nogales
Nov 8, 2011·Annals of Diagnostic Pathology·Shiori Meguro, Masanori Yasuda
May 3, 2013·Nature·Cyriac KandothDouglas A Levine
Jul 28, 2013·Asian Pacific Journal of Cancer Prevention : APJCP·Yi HuRui-Xin Li
Aug 22, 2014·International Journal of Cancer. Journal International Du Cancer·Cornelia KrausAndré Reis
Nov 26, 2015·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Stephen DamatoW Glenn McCluggage
Oct 1, 2014·Indian Journal of Cancer·N AbhilashaS Krishnappa
Mar 15, 2016·Best Practice & Research. Clinical Endocrinology & Metabolism·Anja M SchmittAurel Perren
Jun 1, 2016·Surgical Pathology Clinics·Anne M Mills, Teri A Longacre

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
dissection
PCR

Software Mentioned

TCGA

Related Concepts

Related Feeds

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.